Drug Profile
Research programme: CD26 antigen antagonists - Sun Pharmaceutical Industries
Alternative Names: Dipeptidyl peptidase IV anatagonists - Sun Pharmaceutical Industries; DPP-IV antagonists - Sun Pharmaceutical IndustriesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ranbaxy Laboratories
- Developer Sun Pharmaceutical Industries
- Class Antihyperglycaemics
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in India
- 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
- 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company